
WHAT IS CLAIMED IS:

1. Use of an immune checkpoint inhibitor and a pentaaza macrocyclic ring complex corresponding to formula (II) below,



(II)


wherein

X and Y are Cl; and

R_A, R_B, R_C, and R_D are independently hydrogen

in the manufacture of a medicament for treating cancer, wherein the checkpoint inhibitor is at least one of an anti-CTLA4 antibody, an anti-PD-1 antibody and an anti-PDL-1 antibody, wherein the said pentaaza macrocyclic ring complex is to be administered prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.

2. The use according to claim 1, wherein the pentaaza macrocyclic ring complex is a compound represented by a formula



(4419)

.

3. The use according to any preceding claim, wherein the pentaaza macrocyclic ring complex is to be administered for no less than 3 days after initial administration of the immune checkpoint inhibitor in the course of therapy.

4. The use according to any preceding claim, wherein the pentaaza macrocyclic ring complex is to be administered following two doses of the immune checkpoint inhibitor in the course of therapy.

5. The use according to any preceding claim wherein one or more of an adoptive T-cell transfer and cancer vaccine are to be further administered to the subject, either prior to, concomitantly with, or after administration of one or more of the checkpoint inhibitor and pentaaza macrocyclic ring complex.

6. The use according to any preceding claim, wherein the cancer is selected from the group consisting of breast cancer, non-small-cell lung cancer, melanoma, renal cell carcinoma, urothelial carcinoma, bladder cancer, pancreatic cancer, head and neck cancers, colorectal cancer, prostate cancer, brain cancer, spindle cell carcinoma, and oral squamous cell carcinoma.

7. The use according to any preceding claim, wherein the pentaaza macrocyclic ring complex is to be administered:

i) to the subject in a dose in a range of from 0.2 mg/kg to 40 mg/kg; and/or

ii) parenterally, orally, intraperitoneally, subcutaneously, or intravenously.

8. The use according to any preceding claim, wherein the checkpoint inhibitor is:

i) an anti-PD-1 antibody; or

ii) an anti-CTLA4 antibody; or

iii) an anti-PDL-1 antibody.